Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
July 8, 2019 Off

Anika Appoints James Loerop as Executive Vice President of Business Development and Strategic Planning

By BusinessWire

Industry veteran brings extensive experience leading business development groups BEDFORD, Mass.–(BUSINESS WIRE)–Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic…

July 8, 2019 Off

Tango Therapeutics Appoints Reid Huber, PhD, to Board of Directors

By BusinessWire

Leadership strengthened with appointment of Jannik N. Andersen, PhD, Head of Biology and Jeff Caravella, MBA, VP, Finance CAMBRIDGE, Mass.–(BUSINESS…

July 8, 2019 Off

Tango Therapeutics Appoints Reid Huber, PhD, to Board of Directors

By BusinessWire

Leadership strengthened with appointment of Jannik N. Andersen, PhD, Head of Biology and Jeff Caravella, MBA, VP, Finance CAMBRIDGE, Mass.–(BUSINESS…

July 8, 2019 Off

Aptorum Group’s subsidiary Smart Pharma announces Smart Pharma token (SMPT) to be listed on IDAX and LATOKEN

By BusinessWire

VICTORIA, Seychelles–(BUSINESS WIRE)–Aptorum Group Limited (Nasdaq: APM) subsidiary Smart Pharmaceutical is excited to announce that the Smart Pharma Token (“SMPT…

July 8, 2019 Off

Lyra Therapeutics Adds Laura Edgerly-Pflug as Senior Vice President of Technical Operations

By BusinessWire

Company strengthens leadership team by adding industry veteran with extensive experience in process development, manufacturing and quality control WATERTOWN, Mass.–(BUSINESS…

July 8, 2019 Off

RAPT Therapeutics Announces Promotion of Key Research and Development Senior Leaders

By BusinessWire

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company developing oral small molecules for oncology and inflammatory…

July 8, 2019 Off

Zanubrutinib (BeiGene) Overview 2019: An Oral Small Molecule Inhibitor of Bruton’s Tyrosine Kinase, Developed to be More Selective with Less Off-Target Effects than Imbruvica – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Zanubrutinib” report has been added to ResearchAndMarkets.com’s offering. Zanubrutinib (BeiGene) is an oral small molecule inhibitor of Bruton’s…

July 8, 2019 Off

Zanubrutinib (BeiGene) Overview 2019: An Oral Small Molecule Inhibitor of Bruton’s Tyrosine Kinase, Developed to be More Selective with Less Off-Target Effects than Imbruvica – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Zanubrutinib” report has been added to ResearchAndMarkets.com’s offering. Zanubrutinib (BeiGene) is an oral small molecule inhibitor of Bruton’s…

July 8, 2019 Off

Enanta Pharmaceuticals Initiates Phase 1 Clinical Study of EDP-514, its Lead Core Inhibitor for the Treatment of Hepatitis B Virus (HBV)

By BusinessWire

EDP-514 HBV Lead Asset Granted Fast Track Designation from FDA WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused…

July 8, 2019 Off

Enanta Pharmaceuticals Initiates Phase 1 Clinical Study of EDP-514, its Lead Core Inhibitor for the Treatment of Hepatitis B Virus (HBV)

By BusinessWire

EDP-514 HBV Lead Asset Granted Fast Track Designation from FDA WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused…

Posts pagination

Previous 1 … 3,025 3,026 3,027 … 3,606 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine